Noteworthy, while in some cancers, i.e., Non-Small Cell Lung Cancer (NSCLC), tumor cell PD-L1 positivity has been identified as a biomarker for ICI intervention (47), in MFS, it is still a matter of debate. This evidence concerns the gene CD274 and non-small cell lung carcinoma.